Journal of Inflammation Research
Volume 14, 2021 - Issue
Open access
130
Views
16
CrossRef citations to date
0
Altmetric
Original Research
In vivo Pharmacokinetic and Anticancer Studies of HH-N25, a Selective Inhibitor of Topoisomerase I, and Hormonal Signaling for Treating Breast Cancer
Bashir Lawal1 PhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei, 11031, Taiwan;2 Graduate Institute for Cancer Biology & Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, 11031, Taiwanhttps://orcid.org/0000-0003-0676-5875View further author information
, Yu-Cheng Kuo3 Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan;4 School of Post-Baccalaureate Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, 40402, TaiwanView further author information
, Maryam Rachmawati Sumitra1 PhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei, 11031, Taiwan;2 Graduate Institute for Cancer Biology & Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, 11031, TaiwanView further author information
, Alexander T H Wu5 The PhD Program of Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, 11031, Taiwan;6 Clinical Research Center, Taipei Medical University Hospital, Taipei Medical University, Taipei, 11031, Taiwan;7 TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, 11031, Taiwan;8 Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, 11490, TaiwanCorrespondence[email protected] [email protected]
https://orcid.org/0000-0002-0178-6530View further author information
& https://orcid.org/0000-0002-0178-6530View further author information
Hsu-Shan Huang1 PhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei, 11031, Taiwan;2 Graduate Institute for Cancer Biology & Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, 11031, Taiwan;8 Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, 11490, Taiwan;9 School of Pharmacy, National Defense Medical Center, Taipei, 11490, Taiwan;10 PhD Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, 11031, Taiwanhttps://orcid.org/0000-0001-8162-5608View further author information
Pages 4901-4913
|
Published online: 22 Sep 2021
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.